Prescription medicine
Relacorilant Brand names: Lifyorli; first approved as Lifyorli (Copackaged)
Relacorilant (Lifyorli) is a prescription medicine with an FDA approval on record since 2026. No generic is listed in FDA's NDC Directory.
- No generic listed
Check it at the source: the relacorilant FDA label on DailyMed (effective March 26, 2026, Corcept Therapeutics Incorporated); the NDA 220641 record on Drugs@FDA; every relacorilant label on DailyMed.
Highlights of the record
FDA label of March 26, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026
Used for
From the label: indications and usageLIFYORLI is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab [see Clinical Studies ( 14 )].
Forms and strengths
Kit.
On the market
- Earliest approval on file
- March 25, 2026 Lifyorli (Copackaged), Corcept Therap; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- No generic approved
- Labelers listed (NDC)
- 1 of which 0 under generic applications, 1 under brand applications, repackagers included
- Last listed patent
- December 22, 2041 Lifyorli capsules; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- Not in the survey
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 24 through July 30, 2026
What is relacorilant used for?
From the label: indications and usageLIFYORLI is indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab [see Clinical Studies ( 14 )]. LIFYORLI is a glucocorticoid receptor antagonist indicated in combination with nab-paclitaxel for the treatment of adults with platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer who have received one to three prior systemic treatment regimens, at least one of which included bevacizumab.
Source: FDA drug label (Lifyorli), Corcept Therapeutics Incorporated, effective March 26, 2026 (SPL set 6fcebfb5-19d6-4f63-b852-999d68a13729), via openFDA; the full label on DailyMed
Is there a generic for relacorilant (Lifyorli)?
No generic relacorilant is approved (Drugs@FDA, October 8, 2026).
The Orange Book lists 10 patents for Lifyorli capsules: the compound patent runs to May 24, 2033, and the last listed entry to December 22, 2041. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2026 earliest approval on file
- 2041 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What does the relacorilant label say about other medicines?
The relacorilant label names 1 other medicine in its interaction, contraindication or warning sections. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Paclitaxel | drug interactions | Drugs on LIFYORLI in Combination with Nab-Paclitaxel Strong CYP3A Inducers Avoid coadministration of LIFYORLI plus nab-paclitaxel with strong CYP3A inducers. Both relacorilant and paclitaxel are CYP3A substrates. |
Source: FDA drug label (Lifyorli), Corcept Therapeutics Incorporated, effective March 26, 2026 (SPL set 6fcebfb5-19d6-4f63-b852-999d68a13729), via openFDA; the full label on DailyMed
What do FAERS reports show for relacorilant?
The FDA Adverse Event Reporting System holds 24 reports that list relacorilant among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 2 are coded as a death and 17 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What next?
- Relacorilant side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other